Clinical Trials Study
Copyright ©The Author(s) 2015.
World J Gastroenterol. Jun 14, 2015; 21(22): 6965-6973
Published online Jun 14, 2015. doi: 10.3748/wjg.v21.i22.6965
Table 1 Patient demographic and baseline clinical characteristics n (%)
ParameterITT (n = 305)
MITT (n = 262)
8-wk group2-wk groupTotal8-wk group2-wk groupTotal
Age, yr, mean ± SD45.9 ± 12.7244.9 ± 13.1245.4 ± 12.9145.3 ± 12.8845.1 ± 13.3645.2 ± 13.09
Sex
Men80 (51.9)54 (35.8)134 (43.9)74 (54.4)46 (36.5)120 (45.8)
Women74 (48.1)97 (64.2)171 (56.1)62 (45.6)80 (63.5)142 (54.2)
Symptom
Heartburn142 (92.2)136 (90.1)278 (91.1)126 (92.6)113 (89.7)239 (91.2)
Regurgitation138 (89.6)135 (89.4)273 (89.5)124 (91.2)113 (89.7)237 (90.5)
Duration, mo, mean ± SD
Heartburn36.3 ± 56.4735.8 ± 49.0536.1 ± 52.8739.0 ± 59.2039.1 ± 52.5539.0 ± 56.04
Regurgitation36.4 ± 56.7234.9 ± 47.4135.6 ± 52.2438.4 ± 59.2837.7 ± 50.7138.1 ± 55.24
HP test positive48 (31.2)44 (29.1)92 (30.2)39 (28.7)35 (27.8)74 (28.2)
GerdQ score, mean ± SD10.7 ± 1.7810.4 ± 1.8910.5 ± 1.8410.7 ± 1.7610.4 ± 1.9410.6 ± 1.85
Table 2 Adverse events leading to discontinuation of study medication, and their relationship to study medication n (%)
2-wk group (n = 151)
8 wk group (n = 154)
Total (n = 305)
MildModerateMildModerateMildModerate
Patients with at least one AE01 (0.7)3 (1.9)2 (1.3)3 (1.0)3 (1.0)
Gastrointestinal disorders003 (1.9)2 (1.3)3 (1.0)2 (0.7)
Nausea001 (0.6)12 (1.3)21 (0.3)2 (0.7)
Abdominal discomfort001 (0.6)11 (0.6)11 (0.3)1 (0.3)
Constipation0001 (0.6)101 (0.3)
Frequent bowel movements001 (0.6)101 (0.3)0
Abdominal pain, upper0001 (0.6)101 (0.3)
Eye disorders001 (0.6)01 (0.3)0
Vision blurred001 (0.6)01 (0.3)0
Musculoskeletal and connective tissue disorders01 (0.7)0001 (0.3)
Back pain01 (0.7)0001 (0.3)
Renal and urinary disorders01 (0.7)0001 (0.3)
Dysuria01 (0.7)0001 (0.3)
Respiratory, thoracic and mediastinal disorders0001 (0.6)01 (0.3)
Cough0001 (0.6)01 (0.3)